keyword
MENU ▼
Read by QxMD icon Read
search

"phase 3" cancer

keyword
https://www.readbyqxmd.com/read/29342393/hyperthermic-intraperitoneal-chemotherapy-in-ovarian-cancer
#1
Willemien J van Driel, Simone N Koole, Karolina Sikorska, Jules H Schagen van Leeuwen, Henk W R Schreuder, Ralph H M Hermans, Ignace H J T de Hingh, Jacobus van der Velden, Henriëtte J Arts, Leon F A G Massuger, Arend G J Aalbers, Victor J Verwaal, Jacobien M Kieffer, Koen K Van de Vijver, Harm van Tinteren, Neil K Aaronson, Gabe S Sonke
Background Treatment of newly diagnosed advanced-stage ovarian cancer typically involves cytoreductive surgery and systemic chemotherapy. We conducted a trial to investigate whether the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery would improve outcomes among patients who were receiving neoadjuvant chemotherapy for stage III epithelial ovarian cancer. Methods In a multicenter, open-label, phase 3 trial, we randomly assigned 245 patients who had at least stable disease after three cycles of carboplatin (area under the curve of 5 to 6 mg per milliliter per minute) and paclitaxel (175 mg per square meter of body-surface area) to undergo interval cytoreductive surgery either with or without administration of HIPEC with cisplatin (100 mg per square meter)...
January 18, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29339046/stereotactic-body-radiation-therapy-sbrt-for-high-risk-prostate-cancer-where-are-we-now
#2
REVIEW
Alejandro Gonzalez-Motta, Mack Roach
PURPOSE: Stereotactic body radiation therapy (SBRT) is increasingly being used for the management of localized prostate cancer. This trend combined with declining use of brachytherapy (BT) has pushed issues and questions regarding the use of SBRT to the forefront. A systematic literature review was conducted to review the current evidence of biochemical disease-free survival (bDFS) and toxicity of SBRT in high-risk (HR) prostate cancer. METHODS AND MATERIALS: A search was carried out on the PubMed and Embase databases...
December 2, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/29336835/standard-whole-prostate-gland-radiotherapy-with-and-without-lesion-boost-in-prostate-cancer-toxicity-in-the-flame-randomized-controlled-trial
#3
Evelyn M Monninkhof, Juliette W L van Loon, Marco van Vulpen, Linda G W Kerkmeijer, Floris J Pos, Karin Haustermans, Laura van den Bergh, Sofie Isebaert, Gill M McColl, Robert Jan Smeenk, Juus Noteboom, Iris Walraven, Petra H M Peeters, Uulke A van der Heide
PURPOSE: To compare toxicity rates in patients with localized prostate cancer treated with standard fractionated external beam radiotherapy (EBRT) with or without an additional integrated boost to the macroscopically visible tumour. MATERIAL AND METHODS: FLAME is a phase 3 multicentre RCT (NCT01168479) of patients with pathologically confirmed localized intermediate or high-risk prostate cancer. The standard treatment arm (n = 287) received a dose to the entire prostate of 77 Gy in 35 fractions...
January 11, 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/29332135/sequential-versus-simultaneous-use-of-chemotherapy-and-gonadotropin-releasing-hormone-agonist-gnrha-among-estrogen-receptor-er-positive-premenopausal-breast-cancer-patients-effects-on-ovarian-function-disease-free-survival-and-overall-survival
#4
Ying Zhang, Yajie Ji, Jianwei Li, Li Lei, Siyu Wu, Wenjia Zuo, Xiaoqing Jia, Yujie Wang, Miao Mo, Na Zhang, Zhenzhou Shen, Jiong Wu, Zhimin Shao, Guangyu Liu
OBJECTIVE: To investigate ovarian function and therapeutic efficacy among estrogen receptor (ER)-positive, premenopausal breast cancer patients treated with gonadotropin-releasing hormone agonist (GnRHa) and chemotherapy simultaneously or sequentially. METHOD: This study was a phase 3, open-label, parallel, randomized controlled trial (NCT01712893). Two hundred sixteen premenopausal patients (under 45 years) diagnosed with invasive ER-positive breast cancer were enrolled from July 2009 to May 2013 and randomized at a 1:1 ratio to receive (neo)adjuvant chemotherapy combined with sequential or simultaneous GnRHa treatment...
January 13, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29327055/comparing-neoadjuvant-nab-paclitaxel-vs-paclitaxel-both-followed-by-anthracycline-regimens-in-women-with-erbb2-her2-negative-breast-cancer-the-evaluating-treatment-with-neoadjuvant-abraxane-etna-trial-a-randomized-phase-3-clinical-trial
#5
Luca Gianni, Mauro Mansutti, Antonio Anton, Lourdes Calvo, Giancarlo Bisagni, Begoña Bermejo, Vladimir Semiglazov, Marc Thill, Jose Ignacio Chacon, Arlene Chan, Serafin Morales, Isabel Alvarez, Arrate Plazaola, Milvia Zambetti, Andrew D Redfern, Christian Dittrich, Rebecca Alexandra Dent, Domenico Magazzù, Raffaella De Fato, Pinuccia Valagussa, Ignacio Tusquets
Importance: Studies of neoadjuvant chemotherapy regimens using anthracyclines followed by taxanes have reported a doubling of pathological complete remission (pCR) rates compared with anthracycline-based regimens alone. A reverse sequence did not reduce activity. Nab-paclitaxel is an albumin-bound nanoparticle of paclitaxel that allows for safe infusion without premedication, and its use led to a significantly higher rate of pCR in the GeparSepto trial. Objective: To determine whether nab-paclitaxel improves the outcomes of early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting...
January 11, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29326030/patient-reported-outcomes-following-abiraterone-acetate-plus-prednisone-added-to-androgen-deprivation-therapy-in-patients-with-newly-diagnosed-metastatic-castration-naive-prostate-cancer-latitude-an-international-randomised-phase-3-trial
#6
Kim N Chi, Andrew Protheroe, Alfredo Rodríguez-Antolín, Gaetano Facchini, Henrik Suttman, Nobuaki Matsubara, Zhangqun Ye, Bhumsuk Keam, Ronaldo Damião, Tracy Li, Kelly McQuarrie, Bin Jia, Peter De Porre, Jason Martin, Mary B Todd, Karim Fizazi
BACKGROUND: In the LATITUDE trial, addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) improved overall survival compared with placebos plus ADT in patients with newly diagnosed, high-risk, metastatic castration-naive prostate cancer. Understanding the effects of treatments on patient-reported outcomes (PROs) and health-related quality of life (HRQOL) is important for treatment decisions; therefore we aimed to analyse the effects of ADT plus abiraterone acetate and prednisone versus ADT plus placebos on PROs and HRQOL in patients in the LATITUDE study...
January 8, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29319030/efficacy-of-gefitinib-in-epidermal-growth-factor-receptor-activating-mutation-positive-nonsmall-cell-lung-cancer-does-exon-19-deletion-differ-from-exon-21-mutation
#7
Amit Joshi, Vijay Patil, Vanita Noronha, Anuradha Chougule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
BACKGROUND: This study was designed to evaluate the differential effect of epidermal growth factor receptor (EGFR) mutation status (exon 19 vs. 21) on progression-free survival (PFS) and overall survival (OS) in treatment-naïve advanced EGFR mutation-positive nonsmall cell lung cancer (NSCLC) treated with gefitinib as first-line agent. METHODS: This was a post hoc analysis of EGFR-mutated (exon 19 and 21) advanced-stage (Stage IIIB or IV), chemotherapy-naive NSCLC patients treated with gefitinib as first line in a phase 3 randomized study...
January 2018: Lung India: Official Organ of Indian Chest Society
https://www.readbyqxmd.com/read/29318031/para-aortic-lymphadenectomy-in-advanced-stage-cervical-cancer-a-protocol-for-comparing-safety-feasibility-and-diagnostic-accuracy-of-surgical-staging-versus-pet-ct-paldisc-trial
#8
Casper Tax, Karin Abbink, Maroeska M Rovers, Ruud L M Bekkers, Petra L M Zusterzeel
Background: Currently, a PET-CT is used to assess the need for extended field radiotherapy of para-aortic lymph nodes (PALN) in International Federation of Gynaecology and Obstetrics (FIGO) stage IB2, IIA2-IVA (locally advanced stage) cervical cancer. A small study established a sensitivity and specificity estimate for PALN metastases of 50% (95% CI; 7-93%) and 83% (95% CI; 52-98%), respectively. Surgical staging of PALN may lead to a higher diagnostic accuracy. However, surgical staging of para-aortic lymph nodes in locally advanced stage cervical cancer is not common practice...
2018: Pilot and Feasibility Studies
https://www.readbyqxmd.com/read/29305254/pelvic-floor-functional-outcomes-after-total-abdominal-versus-total-laparoscopic-hysterectomy-for-endometrial-cancer
#9
Peta Higgs, Monika Janda, Rebecca Asher, Val Gebski, Peta Forder, Andreas Obermair
BACKGROUND: Pelvic floor functioning is an important concern for women requiring a hysterectomy for endometrial cancer. The incidence of pelvic floor symptoms has not been reported in women who have undergone a hysterectomy for early-stage endometrial cancer. OBJECTIVES: To evaluate pelvic floor function in women who have had surgical treatment for early stage endometrial cancer as part of the multinational Laparoscopic Approach to Cancer of the Endometrium (LACE) trial and to compare patients' outcomes who had total abdominal total versus total laparoscopic hysterectomy...
January 2, 2018: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29302858/subgroup-analysis-of-patients-with-her2-negative-metastatic-breast-cancer-in-the-second-line-setting-from-a-phase-3-open-label-randomized-study-of-eribulin-mesilate-versus-capecitabine
#10
Xavier Pivot, Seock Ah Im, Matthew Guo, Frederik Marmé
This post hoc subgroup analysis of a large phase 3 study compared the efficacy and safety of eribulin versus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who received second-line treatment. In the phase 3 study, women with advanced/metastatic breast cancer and ≤ 3 prior chemotherapies were randomized 1:1 to eribulin mesilate 1.4 mg/m2 intravenously on days 1 and 8, or twice-daily oral capecitabine 1.25 g/m2 on days 1-14 (21-day cycles)...
January 4, 2018: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/29298706/minimally-invasive-versus-open-pancreatoduodenectomy-leopard-2-study-protocol-for-a-randomized-controlled-trial
#11
Thijs de Rooij, Jony van Hilst, Koop Bosscha, Marcel G Dijkgraaf, Michael F Gerhards, Bas Groot Koerkamp, Jeroen Hagendoorn, Ignace H de Hingh, Tom M Karsten, Daan J Lips, Misha D Luyer, I Quintus Molenaar, Hjalmar C van Santvoort, T C Khé Tran, Olivier R Busch, Sebastiaan Festen, Marc G Besselink
BACKGROUND: Data from observational studies suggest that minimally invasive pancreatoduodenectomy (MIPD) is superior to open pancreatoduodenectomy regarding intraoperative blood loss, postoperative morbidity, and length of hospital stay, without increasing total costs. However, several case-matched studies failed to demonstrate superiority of MIPD, and large registry studies from the USA even suggested increased mortality for MIPDs performed in low-volume (<10 MIPDs annually) centers...
January 3, 2018: Trials
https://www.readbyqxmd.com/read/29288764/brief-report-tivantinib-in-combination-with-erlotinib-versus-erlotinib-alone-for-egfr-mutant-nsclc-an-exploratory-analysis-of-the-phase-3-marquee-study
#12
Giorgio V Scagliotti, Dale Shuster, Sergey Orlov, Joachim von Pawel, Frances A Shepherd, Jeffrey S Ross, Qiang Wang, Brian Schwartz, Wallace Akerley
INTRODUCTION: This exploratory subgroup analysis of the MARQUEE study evaluated the efficacy and safety of erlotinib plus tivantinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). METHODS: Patients with advanced, non-squamous, EGFR and mesenchymal-epithelial transition (MET) inhibitor-naive NSCLC, previously treated with 1 to 2 lines of systemic therapy, were randomized to oral erlotinib (150 mg once daily) plus tivantinib (360 mg twice daily) or to erlotinib plus placebo...
December 27, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29283332/diverse-signaling-pathways-and-current-status-of-molecular-targeted-treatments-for-hepatocellular-carcinoma
#13
Bushra Akhtar, Faqir Muhammad, Ali Sharif, Muhammad Furqan Akhtar, Wafa Majeed
Hepatocellular carcinoma (HCC) is one of the leading causes of death associated with cancer. Various molecular mechanisms are involved in HCC development. Alterations in these molecular mechanisms include chromosomal instability, gene mutations, and variations in protein expressions. A number of cell signaling pathways that are associated with the occurrence of apoptosis, cell proliferation, and angiogenesis provide new prospects for the development of HCC treatments. Newly designed, potential therapeutic regimens target specific receptors, kinases, and vital proteins...
2017: Critical Reviews in Eukaryotic Gene Expression
https://www.readbyqxmd.com/read/29280448/effect-of-breast-irradiation-on-cardiac-disease-in-women-enrolled-in-bcirg-001-at-10-year-follow-up
#14
S Peter Wu, Moses Tam, Raymond Mailhot Vega, Carmen A Perez, Naamit Kurshan Gerber
PURPOSE: To investigate cardiac toxicity associated with breast radiation therapy (RT) at 10-year follow-up in BCIRG-001, a phase 3 trial comparing adjuvant anthracycline chemotherapy (fluorouracil, doxorubicin, and cyclophosphamide) with anthracycline-taxane chemotherapy (docetaxel, doxorubicin, and cyclophosphamide) in women with lymph node-positive early breast cancer. METHODS AND MATERIALS: Prospective data from all 746 patients in the control arm (fluorouracil, doxorubicin, and cyclophosphamide) of BCIRG-001 at 10-year follow-up were obtained from Project Data Sphere...
November 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29275118/rituximab-maintenance-versus-observation-following-abbreviated-induction-with-chemoimmunotherapy-in-elderly-patients-with-previously-untreated-chronic-lymphocytic-leukaemia-cll-2007-sa-an-open-label-randomised-phase-3-study
#15
Caroline Dartigeas, Eric Van Den Neste, Julie Léger, Hervé Maisonneuve, Christian Berthou, Marie-Sarah Dilhuydy, Sophie De Guibert, Stéphane Leprêtre, Marie C Béné, Florence Nguyen-Khac, Rémi Letestu, Florence Cymbalista, Philippe Rodon, Thérèse Aurran-Schleinitz, Jean-Pierre Vilque, Olivier Tournilhac, Béatrice Mahé, Kamel Laribi, Anne-Sophie Michallet, Alain Delmer, Pierre Feugier, Vincent Lévy, Roselyne Delépine, Philippe Colombat, Véronique Leblond
BACKGROUND: Most patients with chronic lymphocytic leukaemia relapse after initial therapy combining chemotherapy with rituximab. We assessed the efficacy and safety of rituximab maintenance treatment versus observation for elderly patients in remission after front-line abbreviated induction by fludarabine, cyclophosphamide, and rituximab (FCR). METHODS: This randomised, open-label, multicentre phase 3 trial at 89 centres in France enrolled treatment-naive and fit patients aged 65 years or older with chronic lymphocytic leukaemia without del(17p)...
December 20, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/29260599/alisertib-a-review-of-pharmacokinetics-efficacy-and-toxicity-in-patients-with-hematologic-malignancies-and-solid-tumors
#16
Susanne Liewer, Ashley Huddleston
Aurora kinases are essential mediators in cell mitosis. Amplification of these kinases can lead to the development of malignancy and may be associated with inferior survival. Alisertib is an oral aurora kinase inhibitor which has been shown to induce cell-cycle arrest and apoptosis in preclinical studies. It is currently under investigation for a wide variety of malignancies including hematologic (specifically Non-Hodgkin's lymphoma) and solid tumors. Areas covered: A PubMed search was performed to identify clinical studies reporting outcomes with alisertib...
December 20, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/29250204/asco-update-gastrointestinal-tumors
#17
REVIEW
Lukas Weiss, Florian Huemer, Richard Greil
A multitude of new molecular and immunologic insights into gastrointestinal tumors have been presented at the ASCO meeting 2017; however, we have focused our update on practice-changing phase 3 trials and tried to set them into clinical perspective. Furthermore, we will elaborate on updated data on immunotherapeutics in gastroesophageal cancers, since drug approvals may be anticipated before convening for the next meeting in 2018.
2017: Memo
https://www.readbyqxmd.com/read/29239137/medical-management-of-gastric-cancer-a-2017-update
#18
REVIEW
Nikolaos Charalampakis, Panagiota Economopoulou, Ioannis Kotsantis, Maria Tolia, Dimitrios Schizas, Theodore Liakakos, Elena Elimova, Jaffer A Ajani, Amanda Psyrri
Gastric cancer remains a considerable health burden throughout the world. The Cancer Genome Atlas (TCGA) analysis has recently unveiled 4 genotypes of gastric cancer with data not ready to change treatment strategy yet. A multimodality approach to therapy is the cornerstone of screening, diagnosing, staging, treating and supporting patients with gastric cancer. The evidence-based approach to localized gastric cancer (>cT1b) is to use an either preoperative or postoperative strategy to maximize the benefit of surgery...
December 13, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/29233548/the-impact-of-actual-body-weight-based-chemotherapy-dosing-and-body-size-on-adverse-events-and-outcome-in-older-patients-with-breast-cancer-results-from-cancer-and-leukemia-group-b-calgb-trial-49907-alliance-a151436
#19
Vicki A Morrison, Linda McCall, Hyman B Muss, Aminah Jatoi, Harvey J Cohen, Constance T Cirrincione, Jennifer A Ligibel, Jacqueline M Lafky, Arti Hurria
OBJECTIVE: Actual weight-based (AWB) chemotherapy dosing is recommended for obese patients in the 2012 ASCO Clinical Practice Guideline. CALGB 49907, which utilized ABW-based adjuvant chemotherapy dosing, was a phase 3 trial in women age≥65years with early stage breast cancer, providing the opportunity to examine impact of such dosing on toxicities and outcome in older patients with breast cancer. MATERIALS AND METHODS: Adverse event data were available for 615 of 633 enrolled patients...
December 7, 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/29230663/advantages-with-prophylactic-peg-rhg-csf-versus-rhg-csf-in-breast-cancer-patients-receiving-multiple-cycles-of-myelosuppressive-chemotherapy-an-open-label-randomized-multicenter-phase-iii-study
#20
Jie Xie, Jun Cao, Jing-Fen Wang, Bai-Hong Zhang, Xiao-Hua Zeng, Hong Zheng, Yang Zhang, Li Cai, Yu-Dong Wu, Qiang Yao, Xiao-Chun Zhao, Wei-Dong Mao, Ai-Mei Jiang, Shao-Shui Chen, Shun-E Yang, Shu-Sen Wang, Jian-Hong Wang, Yue-Yin Pan, Bi-Yong Ren, Yan-Ju Chen, Li-Zhi Ouyang, Kai-Jian Lei, Jing-Hua Gao, Wen-He Huang, Zhan Huang, Tao Shou, Yan-Ling He, Jing Cheng, Yang Sun, Wei-Ming Li, Shu-de Cui, Xin Wang, Zhi-Guo Rao, Hu Ma, Wei Liu, Xue-Yong Wu, Wei-Xi Shen, Fei-Lin Cao, Ze-Min Xiao, Biao Wu, Shu-Yan Tian, Dong Meng, Peng Shen, Bi-Yun Wang, Zhonghua Wang, Jian Zhang, Leiping Wang, Xi-Chun Hu
BACKGROUND: PEG-rhG-CSF reduces neutropenia and improves chemotherapy safety. In China's registration trial (CFDA: 2006L01305), we assessed its efficacy and safety against rhG-CSF, and prospectively explored its value over multiple cycles of chemotherapy. METHODS: In this open-label, randomized, multicenter phase 3 study, breast cancer patients (n = 569) were randomized to receive PEG-rhG-CSF 100 µg/kg, PEG-rhG-CSF 6 mg, or rhG-CSF 5 µg/kg/d after chemotherapy...
December 11, 2017: Breast Cancer Research and Treatment
keyword
keyword
91260
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"